Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020)

Alx Oncology Holdings' Preferred Stock Liabilities history spans 2 years, with the latest figure at $175.0 million for Q2 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 148.77% to $175.0 million in Q2 2020 year-over-year; TTM through Jun 2020 was $175.0 million, a 148.77% increase, with the full-year FY2019 number at $70.4 million, up 15.48% from a year prior.
  • Preferred Stock Liabilities hit $175.0 million in Q2 2020 for Alx Oncology Holdings, roughly flat from $175.0 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for ALXO hit a ceiling of $175.0 million in Q1 2020 and a floor of $70.4 million in Q2 2019.